Deals channel feed – Endpoints News

Deals channel feed

Danaher strikes deal to buy booming next-gen manufacturer Aldevron for $9.6B

4 years ago

Chinese oncology specialist Zai Lab brokers a deal with MacroGenics for up to 4 bispecifics with a modest down payment

4 years ago

Amid sluggish sales and dueling lawsuits, Novartis bows out of Amgen partnership, slashes staff

4 years ago

Exscientia spends SoftBank's cash in bid to edge out AI rivals

4 years ago

CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida

4 years ago

Top analyst maps a rocky road for Vertex — unless they adopt a $10B M&A campaign to save the pipeline

4 years ago

Hal Barron gambles $625M cash on high-wire TIGIT act, throwing GlaxoSmithKline into heated race and completing next-gen I/O trinity

4 years ago

Sid Mukherjee's Vor taps a CAR-T development partner to strap to its attempt at better stem cell transplants

4 years ago

Flagship and Khosla Ventures team up for biotech's latest SPAC, with Valo Health winning a blank check ticket to Nasdaq

4 years ago

Roivant's data spinout merges with rival in $7B deal

4 years ago

BeiGene dives in on natural killer cells with discovery pact for small biotech's stem cell-based platform

4 years ago

On a continued hunt for Parkinson's breakthroughs, AbbVie turns to a biotech in its portfolio

4 years ago

Keen to turn a new page, Indivior branches out, picking up an option for cannabis addiction drug

4 years ago

J&J breaks off alliance with argenx, dropping CD70 AML drug and axing $1.3B in biobucks

4 years ago

'Autonomy with bridges': The chief architect of the Alexion buyout is now headed over to take command. Here's what he's thinking

4 years ago

Bayer doubles down on radiotherapy with acquisitions of 2 tiny biotech players built around research from Cornell

4 years ago

Genmab enlists another antibody conjugate partner, teaming up with Bolt to develop up to 3 cancer programs

4 years ago

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

4 years ago

Novartis plots 'next frontier' of MS treatment — and it could spell a buyout for a small Swiss player

4 years ago

Mirati wins over a Chinese partner for KRAS hopeful, looking to tail Amgen's breakthrough win

4 years ago

Amgen beefs up its late-stage pipeline with a $400M cash deal to go up against heavyweight rivals in a PhIII atopic dermatitis showdown

4 years ago

Looking to build new smart cells, BlueRock teams with Tim Lu's Senti Bio in 'second-order' engineering alliance

4 years ago

Three years after pivoting out of disaster, Vectura gets a $1.4B private equity buyout

4 years ago

UK begins inquiry into AstraZeneca's $39B buyout of Alexion

4 years ago

First page Previous page 74 75 767778 79 80 Next page Last page